BSX Quote, Financials, Valuation and Earnings

Integer Holdings has a net margin of 14.45% compared to Boston Scientific's net margin of -5.14%. Boston Scientific's return on equity of 9.57% beat Integer Holdings's return on equity of 4.85%.

Boston Scientific has a consensus price target of $117.02, signalling upside risk potential of 17.33%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 25.74%. Given that Integer Holdings has higher upside potential than Boston Scientific, analysts believe Integer Holdings is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.681, which suggesting that the stock is 31.908% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.979, suggesting its less volatile than the S&P 500 by 2.088%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Integer Holdings quarterly revenues of $437.4M. Boston Scientific's net income of $674M is higher than Integer Holdings's net income of -$22.5M. Notably, Boston Scientific's price-to-earnings ratio is 72.80x while Integer Holdings's PE ratio is 56.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 2.39x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 14.45% compared to Boston Scientific's net margin of -45.89%. Boston Scientific's return on equity of 9.57% beat Masimo's return on equity of -39.91%.

Boston Scientific has a consensus price target of $117.02, signalling upside risk potential of 17.33%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 12.95%. Given that Boston Scientific has higher upside potential than Masimo, analysts believe Boston Scientific is more attractive than Masimo.

Boston Scientific has a beta of 0.681, which suggesting that the stock is 31.908% less volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.725%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Masimo quarterly revenues of $372M. Boston Scientific's net income of $674M is higher than Masimo's net income of -$170.7M. Notably, Boston Scientific's price-to-earnings ratio is 72.80x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 4.43x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 14.45% compared to Boston Scientific's net margin of 6.22%. Boston Scientific's return on equity of 9.57% beat Insulet's return on equity of 36.9%.

Boston Scientific has a consensus price target of $117.02, signalling upside risk potential of 17.33%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.89%. Given that Boston Scientific has higher upside potential than Insulet, analysts believe Boston Scientific is more attractive than Insulet.

Boston Scientific has a beta of 0.681, which suggesting that the stock is 31.908% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Insulet quarterly revenues of $569M. Boston Scientific's net income of $674M is higher than Insulet's net income of $35.4M. Notably, Boston Scientific's price-to-earnings ratio is 72.80x while Insulet's PE ratio is 54.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 10.25x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 14.45% compared to Boston Scientific's net margin of 11.15%. Boston Scientific's return on equity of 9.57% beat Stryker's return on equity of 14.2%.

Boston Scientific has a consensus price target of $117.02, signalling upside risk potential of 17.33%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 11.7%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.681, which suggesting that the stock is 31.908% less volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.7B, which are smaller than Stryker quarterly revenues of $5.9B. Boston Scientific's net income of $674M is higher than Stryker's net income of $654M. Notably, Boston Scientific's price-to-earnings ratio is 72.80x while Stryker's PE ratio is 50.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 6.27x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.